FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to dermatology, and concerns using BRaf inhibitors for treating skin reactions. That is ensured by administering an effective amount of a BRaf inhibitor exhibiting a paradoxical mitogen-activated protein kinase activation effect.
EFFECT: due to this paradoxical effect, effective correction of skin disorders caused by treatment of epidermal growth factor receptor (EGFR) inhibitor and/or phosphoinositide-3-kinase (PI3K) inhibitor.
15 cl, 4 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEW BRAF INHIBITORS AND THEIR USE FOR TREATMENT OF SKIN REACTIONS | 2018 |
|
RU2779185C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| THERAPEUTIC USE OF MEDICINAL FORMS OF BERBERINE | 2016 |
|
RU2733743C2 |
| USE OF COMPOSITIONS BASED ON BRaf INHIBITOR FOR EXTERNAL USE FOR TREATMENT OF RADIATION DERMATITIS | 2020 |
|
RU2812708C2 |
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| APOPTOSIS-INDUCING MEANS | 2011 |
|
RU2639459C2 |
| COMBINATION THERAPY | 2013 |
|
RU2677245C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| NEW METHYLQUINAZOLINONE DERIVATIVES | 2020 |
|
RU2802968C1 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
